Prognosis Research: A Strategic Initiative in Translational Pathways (PROGRESS)
Lead Research Organisation:
University College London
Department Name: Epidemiology and Public Health
Abstract
Strategic importance A basic form of clinical enquiry involves characterising people with disease or illness at one time point and following them up to see whether and why they have progressed at another time point. Such prognosis research is important in understanding how to ?translate? new approaches to improving health from initial discovery, through phases of evaluation and, where appropriate, into clinical practice. Prognosis research should complement and add value to MRC strategic aims, relating to: genetics, biomarkers, wellbeing, exploitation of health records and population based data and translational research.
But numerous systematic reviews across different disease areas suggest that there is a gap between the promise of prognosis research and its ability to deliver. As a response to this we have developed a forthcoming series of 6 articles in BMJ/PloSMed which sets out a framework of prognosis research and makes recommendations.
Aim: The aim of the PROGRESS Partnership is to critically develop and systematically apply concepts, methods and recommendations (from the initial PROGRESS article series and elsewhere) across different disease areas in order to enhance the translational impact of prognosis research.
Partnership We will achieve this aim by establishing a new international consortium in translational prognosis research. Investigators in the Partnership (drawn from authors of the 6 article series) lead current prognosis research funding of #66 million. With MRC support the international Partnership will be established across disease areas and methodological disciplines.
Partnership workstreams The Partnership will deliver three inter-related, milestone-driven workstreams: I Enabling activities, through targeted workshops we seek to (a) advance methods development in stratified medicine, which seeks to target treatments at those patients who will benefit the most (b) improve the openness (?transparency?) with which prognosis research is reported in scientific papers, (c) identify opportunities for better research across clinical cohorts and (d) disseminate Partnership findings (knowledge transfer). II New research We will do new research, focussing on examples of where prognosis research is important in translation across our Partnership. We will both look backwards at published literature (knowledge synthesis) and forwards carrying out new analyses in our own clinical cohorts. These include novel opportunities in over 50,000 patients with different diseases: coronary disease; cancer, acute severe bleeding in trauma and childbirth and musculoskeletal disorders. III Training We will develop a range of taught course, higher degree and Fellowship opportunities to develop future national and international leaders in prognosis research.
But numerous systematic reviews across different disease areas suggest that there is a gap between the promise of prognosis research and its ability to deliver. As a response to this we have developed a forthcoming series of 6 articles in BMJ/PloSMed which sets out a framework of prognosis research and makes recommendations.
Aim: The aim of the PROGRESS Partnership is to critically develop and systematically apply concepts, methods and recommendations (from the initial PROGRESS article series and elsewhere) across different disease areas in order to enhance the translational impact of prognosis research.
Partnership We will achieve this aim by establishing a new international consortium in translational prognosis research. Investigators in the Partnership (drawn from authors of the 6 article series) lead current prognosis research funding of #66 million. With MRC support the international Partnership will be established across disease areas and methodological disciplines.
Partnership workstreams The Partnership will deliver three inter-related, milestone-driven workstreams: I Enabling activities, through targeted workshops we seek to (a) advance methods development in stratified medicine, which seeks to target treatments at those patients who will benefit the most (b) improve the openness (?transparency?) with which prognosis research is reported in scientific papers, (c) identify opportunities for better research across clinical cohorts and (d) disseminate Partnership findings (knowledge transfer). II New research We will do new research, focussing on examples of where prognosis research is important in translation across our Partnership. We will both look backwards at published literature (knowledge synthesis) and forwards carrying out new analyses in our own clinical cohorts. These include novel opportunities in over 50,000 patients with different diseases: coronary disease; cancer, acute severe bleeding in trauma and childbirth and musculoskeletal disorders. III Training We will develop a range of taught course, higher degree and Fellowship opportunities to develop future national and international leaders in prognosis research.
Technical Summary
Strategic importance Prognosis research should be a basic science for translational research, clinical practice, personalised medicine and, with increasing periods of the lifecourse lived with chronic disease, for public health. Prognosis research should complement and add value to MRC strategic aims, principally those relating to: genetics, biomarkers, wellbeing, translational research and exploitation of health records and population based data.
But numerous systematic reviews across different disease areas suggest that there is a gap between the promise of prognosis research and its ability to deliver. Internationally there have been no initiatives bringing together prognosis research across early and late stages in translation, across different prognosis research questions, and across disease areas. In short, the field is fragmented. As a response to this we have developed a forthcoming series of 6 articles in BMJ/PloSMed which sets out a framework of prognosis research and makes recommendations.
Aim: The aim of the PROGRESS Partnership is to critically develop and systematically apply concepts, methods and recommendations (from the initial PROGRESS article series and elsewhere) across different disease areas in order to enhance the translational impact of prognosis research.
Partnership We will achieve this aim by establishing a new international consortium in translational prognosis research. Investigators in the Partnership (drawn from authors of the 6 article series) lead current prognosis research funding of #66m. With MRC support we will galvanise these resources with a Partnership across disease areas (cardiovascular, cancer, musculoskeletal, trauma and emergency medicine) and methodological disciplines (biostatistics, epidemiology, genetics, biomarkers, health services research).
Partnership workstreams The Partnership will break new ground in delivering three inter-related, milestone-driven workstreams: I Enabling and underpinning activities, through targeted workshops we will advance methods development in stratified medicine, ?transparency? standards in prognostic models, strategic direction across new and existing prognostic cohorts and knowledge transfer. II New research on translational exemplars involving new knowledge syntheses in stratified medicine (field synopses and high resolution systematic reviews), and new prospective analyses in our Partnership cohorts and trials. We will exploit novel opportunities in coronary disease (cohort with DNA and deep phenotyping n=5000); cancer (new translational DNA, plasma and tissue bioresource cohort of head and neck cancer patients, n=5000), acute severe haemorrhage trials in trauma (n=20,000), post-partum haemorrhage (n=15,000); musculoskeletal disorders n=7000 patients with repeat measures over 7 years. III boosting capability through training developing future national and international leaders in prognosis research through taught courses, PhD studentships, and Fellowships.
But numerous systematic reviews across different disease areas suggest that there is a gap between the promise of prognosis research and its ability to deliver. Internationally there have been no initiatives bringing together prognosis research across early and late stages in translation, across different prognosis research questions, and across disease areas. In short, the field is fragmented. As a response to this we have developed a forthcoming series of 6 articles in BMJ/PloSMed which sets out a framework of prognosis research and makes recommendations.
Aim: The aim of the PROGRESS Partnership is to critically develop and systematically apply concepts, methods and recommendations (from the initial PROGRESS article series and elsewhere) across different disease areas in order to enhance the translational impact of prognosis research.
Partnership We will achieve this aim by establishing a new international consortium in translational prognosis research. Investigators in the Partnership (drawn from authors of the 6 article series) lead current prognosis research funding of #66m. With MRC support we will galvanise these resources with a Partnership across disease areas (cardiovascular, cancer, musculoskeletal, trauma and emergency medicine) and methodological disciplines (biostatistics, epidemiology, genetics, biomarkers, health services research).
Partnership workstreams The Partnership will break new ground in delivering three inter-related, milestone-driven workstreams: I Enabling and underpinning activities, through targeted workshops we will advance methods development in stratified medicine, ?transparency? standards in prognostic models, strategic direction across new and existing prognostic cohorts and knowledge transfer. II New research on translational exemplars involving new knowledge syntheses in stratified medicine (field synopses and high resolution systematic reviews), and new prospective analyses in our Partnership cohorts and trials. We will exploit novel opportunities in coronary disease (cohort with DNA and deep phenotyping n=5000); cancer (new translational DNA, plasma and tissue bioresource cohort of head and neck cancer patients, n=5000), acute severe haemorrhage trials in trauma (n=20,000), post-partum haemorrhage (n=15,000); musculoskeletal disorders n=7000 patients with repeat measures over 7 years. III boosting capability through training developing future national and international leaders in prognosis research through taught courses, PhD studentships, and Fellowships.
